"Pyrazinamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazine that is used therapeutically as an antitubercular agent.
| Descriptor ID |
D011718
|
| MeSH Number(s) |
D03.383.679.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazinamide".
Below are MeSH descriptors whose meaning is more specific than "Pyrazinamide".
This graph shows the total number of publications written about "Pyrazinamide" by people in this website by year, and whether "Pyrazinamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 5 | 7 | 12 |
| 2018 | 5 | 1 | 6 |
| 2019 | 3 | 4 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrazinamide" by people in Profiles.
-
Plain 1 H nuclear magnetic resonance analysis streamlines the quality control of antiviral favipiravir and congeneric World Health Organization essential medicines. Magn Reson Chem. 2021 07; 59(7):746-751.
-
Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. J Antimicrob Chemother. 2019 12 01; 74(12):3537-3545.
-
Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. Eur Respir J. 2019 10; 54(4).
-
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations. BMC Infect Dis. 2019 Sep 09; 19(1):794.
-
Individualising therapy for drug-sensitive tuberculosis. Lancet Respir Med. 2019 10; 7(10):834-835.
-
Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study. J Infect Chemother. 2019 Dec; 25(12):1026-1030.
-
Severe disseminated tuberculosis in HIV-negative refugees. Lancet Infect Dis. 2019 10; 19(10):e352-e359.
-
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Trials. 2019 Jan 16; 20(1):57.
-
Insights into the Mechanisms of the Pyrazinamide Resistance of Three Pyrazinamidase Mutants N11K, P69T, and D126N. J Chem Inf Model. 2019 01 28; 59(1):498-508.
-
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling. Antimicrob Agents Chemother. 2018 12; 62(12).